Expression of MMP-8 and MMP-13 in the development of periradicular lesions

AIM

To elucidate the expressions of MMP-8 and MMP-13 in experimentally induced rat periradicular lesions by means of the reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemical staining.

METHODOLOGY

Thirty rats were used and periradicular lesions in mandibular first molar teeth were established following pulp exposure. The animals were sacrificed at 0 (no exposure control), 1, 2, 3, 4 and 6 weeks after pulp exposure. The right molars were used for RT-PCR analysis of MMP-8 and MMP-13. The left molars were subjected to immunohistochemical staining with both MMPs. The areas of these lesions were measured histometrically, and the numbers of both reactive cells in the periapical portion were counted per unit area. Significant differences were analysed by the Mann-Whitney U-test.

RESULTS

MMP-8 gene expression gradually increased from 2 to 4 weeks, but slightly decreased at 6 weeks. MMP-13 gene expression gradually increased from 1 to 3 weeks. At 4 and 6 weeks, the level of expression was as high as that at 3 weeks. Immunohistochemically, MMP-8 was first detected at 2 weeks and gradually increased until 4 weeks. MMP-13 gradually increased from 1 to 4 weeks. Both MMPs decreased at 6 weeks. The area of the periradicular lesions gradually increased from 1 to 4 weeks, showing a large increase in week 2 and 3 in particular, but then decreased in week 6. MMP-13-expressing cells were significantly greater than MMP-8-positive cells at week 1 and 2.

CONCLUSIONS

These findings indicate that MMP-8 and MMP-13 were related to the development of periradicular lesions. It is suggested that MMP-13 increased from an early stage during their development and that MMP-8 is involved in the progression of tissue destruction including bone resorption.

The inhibitory effects of intravenous administration of rabbit immunoglobulin G on airway inflammation are dependent upon Fcγ receptor IIb on CD11c(+) dendritic cells in a murine model

Immunoglobulins (Igs) play important immunomodulatory effects on allergic asthma. Among these, IgG has been reported to regulate allergic inflammation in previous studies about immunotherapy and intravenous immunoglobulin therapy. In this study, to examine the immunomodulatory mechanisms of IgG and FcRs we evaluated the effects of intravenous (i.v.) rabbit IgG administration (IVIgG) on allergic airway inflammation and lung antigen-presenting cells (APCs) in a murine model of ovalbumin (OVA) sensitization and challenge. In OVA-challenged mice, IVIgG attenuated airway eosinophilia, airway hyperresponsiveness and goblet cell hyperplasia and also inhibited the local T helper type (Th) 2 cytokine levels. Additionally, IVIgG attenuated the proliferation of OVA-specific CD4(+) T cells transplanted into OVA-challenged mice. Ex vivo co-culture with OVA-specific CD4(+) cells and lung CD11c(+) APCs from mice with IVIgG revealed the attenuated transcription level of Th2 cytokines, suggesting an inhibitory effect of IVIgG on CD11c(+) APCs to induce Th2 response. Next, to analyse the effects on Fcγ receptor IIb and dendritic cells (DCs), asthmatic features in Fcγ receptor IIb-deficient mice were analysed. IVIgG failed to attenuate airway eosinophilia, airway inflammation and goblet cell hyperplasia. However, the lacking effects of IVIgG on airway eosinophilia in Fcγ receptor IIb deficiency were restored by i.v. transplantation of wild-type bone marrow-derived CD11c(+) DCs. These results demonstrate that IVIgG attenuates asthmatic features and the function of lung CD11c(+) DCs via Fcγ receptor IIb in allergic airway inflammation. Targeting Fc portions of IgG and Fcγ receptor IIb on CD11c(+) DCs in allergic asthma is a promising therapeutic strategy.

Thermodynamic investigation of coordination-networked systems of [Mn4] single-molecule magnets under pressure

Low temperature heat capacity measurements under pressure were performed for tiny single crystals of two-dimensional coordination-networked compounds consisting of [Mn(4)] single-molecule magnets (SMMs) by the ac temperature modulation technique. Systematic variations of the peak temperature and the peak width of the thermal anomalies produced by pressure were clearly detected using two ruthenium oxide resistance chips in the Cu-Be clamp-type cell. A linear increase of the Néel temperature for an ordering set of large SMM spins with S=9 was observed in [Mn(4)(hmp)(6){N(CN)(2)}(2)](ClO(4))(2), while a non-monotonic variation of the peak temperatures and peak shapes was observed in [Mn(4)(hmp)(4)Br(2)(OMe)(2){N(CN)(2)}(2)](ClO(4))(2)·2THF·0.5H(2)O (hmp(-)=2-hydroxymethylpyridinate; N(CN)(2)(-)=dicyanamide as the linker among SMMs). We also report on thermodynamic behavior produced by changing external pressures and magnetic fields. The results are discussed in terms of the tilting angle of Ising axes in the two-dimensional plane.

Pirfenidone in idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease without proven effective therapy. A multicentre, double-blind, placebo-controlled, randomised phase III clinical trial was conducted in Japanese patients with well-defined IPF to determine the efficacy and safety of pirfenidone, a novel antifibrotic oral agent, over 52 weeks. Of 275 patients randomised (high-dose, 1,800 mg x day(-1); low-dose, 1,200 mg x day(-1); or placebo groups in the ratio 2:1:2), 267 patients were evaluated for the efficacy of pirfenidone. Prior to unblinding, the primary end-point was revised; the change in vital capacity (VC) was assessed at week 52. Secondary end-points included the progression-free survival (PFS) time. Significant differences were observed in VC decline (primary end-point) between the placebo group (-0.16 L) and the high-dose group (-0.09 L) (p = 0.0416); differences between the two groups (p = 0.0280) were also observed in the PFS (the secondary end-point). Although photosensitivity, a well-established side-effect of pirfenidone, was the major adverse event in this study, it was mild in severity in most of the patients. Pirfenidone was relatively well tolerated in patients with IPF. Treatment with pirfenidone may decrease the rate of decline in VC and may increase the PFS time over 52 weeks. Additional studies are needed to confirm these findings.

Reduction rate of neptunium(V) in heterogeneous solution with magnetite

The sorption kinetics of neptunium on magnetite was investigated under both aerobic and anaerobic conditions in 0.1mol L-1 NaNO3 at pH=5.7 to 5.9. It was found that the sorption of neptunium on magnetite reaches an equilibrium in 1h under aerobic conditions, while it takes 10h or more to reach the equilibrium under anaerobic conditions. The difference in sorption kinetics between aerobic and anaerobic conditions took place because sorption kinetics under the anaerobic condition involved the reduction of Np(V) to Np(IV), confirmed by an extraction technique using 0.5mol L-1 TTA in xylene and 2.0mol L-1 HNO3 solution. The reduction rate of Np(V) by Fe(II) in magnetite was calculated in solution with magnetite. It was found that Np(V) was reduced 1000 or more times faster in solution with magnetite than the Np(V) reduction by Fe(II) ions in homogeneous solution. It was revealed that the reduction of Np(V) in solution with magnetite took place on the surface of magnetite.

Sorption and reduction of neptunium(V) on the surface of iron oxides

Sorption and desorption experiments of Np on magnetite and hematite under aerobic and anaerobic conditions were carried out to investigate the possibility of reduction of Np(V) to Np(IV) at pH 4 to 8 within 7 days. The amount of sorbed Np on magnetite under anaerobic conditions was about 2 or 3 times greater than that under aerobic conditions. Furthermore, the results of desorption experiments indicated that the dominant sorption behavior of Np on magnetite under anaerobic conditions was quite different from that under aerobic conditions. The oxidation state of Np sorbed on the iron oxides was determined by extraction technique using 0.5 M TTA in xylene and 2.0 M HNO3solution from the solid phase after sorption experiment. 90% and 10% of extracted Np was Np(IV) for magnetite system under anaerobic and aerobic conditions, respectively. On the other hand, almost 100% of extracted Np was Np(V) for hematite system under both aerobic and anaerobic conditions. These results indicated that Np(V) was reduced to Np(IV) by Fe(II) in magnetite.

Redox reaction between Np(V) and Fe(II) was also studied in homogeneous solution without solid to decide if Fe(II) ions released from magnetite into silution or Fe(II) on the solid cause the reduction. Only 6% of Np(V) was reduced by Fe(II) at pH=4 and 6 even after 7 days. According to this result, it was conjectured that the reduction of Np(V) to Np(IV) takes place not in the liquid phase by Fe(II) ion but on the surface of magnetite.

Sorption and desorption kinetics of Np(V) on magnetite and hematite

Sorption kinetics of Np(V) on magnetite and hematite were investigated, and a sequential desorption method was applied to investigate changes in the chemical form of Np sorbed according to the amount of time they were in contact with the Np solution. It was found that the sorption process consists of fast sorption and slow sorption which reaches equilibrium in 1 h. According to the desorption results, it was conjectured (i) that fast sorption is attributable to sorption on/into the surface and non-crystalline phases of iron oxides for magnetite and hematite in both acidic and alkaline solutions, (ii) that sorption on/into the crystalline phase also contributes to fast sorption for hematite in an alkaline solution, and (iii) that slow sorption represents sorption into the crystalline phase of magnetite in both acidic and alkaline solutions and that of hematite in an acidic solution. From the results of sorption and desorption kinetics, it was concluded that the equilibrium between various chemical forms of sorbed Np was achieved in about 1 week, although the amount of sorbed Np reached an equilibrium in only 1 h.

A resonating broken symmetry configuration interaction approach for double-exchange magnetic systems

The correct description for ion-radical systems has recently attracted much attention from density functional theory (DFT) researchers. Although several hybridization schemes using exact (Hartree-Fock) exchange and DFT exchange-correlation functionals have been proposed, it has been reported that such treatments do not work for the description of ion-radical systems. In this study we show that combining the exact exchange term in the Kohn-Sham DFT (or the Hartree-Fock equation) with the following resonating configuration interaction method is effective for the description of double-exchange type molecular magnetic interactions. The results are analyzed in relation to the 'many-electron self-interaction' concept that was recently proposed by DFT researchers.

Comparison of human serum with fetal bovine serum for expansion and differentiation of human synovial MSC: potential feasibility for clinical applications

The aim of this study was to evaluate the effect of human serum (HS) on growth and differentiation capacity of human synovium-derived mesenchymal stem cells (MSC) in comparison to cells grown in fetal bovine serum (FBS). Human MSCs were isolated from the synovium of knee joints of three donors and the cells were cultured individually in varying concentrations of allogenic HS or FBS. Bovine MSCs were isolated from synovium and cultured in the same manner. Cell proliferation was assessed by the tetrazolium assay after passage 3. The capacity for chondrogenic and osteogenic differentiation was investigated in specific media followed by 1,9-dimethylmethylene blue assay and alcian blue staining, or by alizarin red staining, respectively. Human MSCs proliferated significantly more rapidly in the presence of HS than with equivalent levels of FBS. Chondrogenic or osteogenic differentiation occurred to nearly identical levels in HS or FBS. The results of this study indicate that HS is superior for the culture of human MSCs compared with FBS in terms of cellular expandability, without losing chondrogenic or osteogenic differentiation capacity. Coupled with the advantage in eliminating the potential risk accompanied with the use of xeno-derived materials, pooled, well-characterized HS could be a useful reagent to promote cellular expansion for clinical synovial stem cell-based therapy.